The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …

Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …

PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …

Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
- Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European …

The treatment of breast cancer has improved dramatically over the past century, from a
strictly surgical approach to a coordinated one, including local and systemic therapies …

PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2–(ClinicalTrials. gov identifier:
NCT01779206; n= 5,625 registered) is the first trial combining the 21-gene expression …

The 18th St Gallen International Breast Cancer Conference held in March 2023, in Vienna,
Austria, assessed significant new findings for local and systemic therapies for early breast …

Simple Summary In breast cancer development, the expression of Ki-67 is strongly
associated with cancer proliferation and is a known indicator of prognosis and outcome. Ki …

Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with
oestrogen receptor positive (ER+) breast cancer (BC), but> 20% of patients will eventually …